• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks
    cannabis investing

    Revive Therapeutics Shares Data from Cannabinoid-Based Therapies Research

    Bryan Mc Govern
    Jun. 07, 2017 08:46AM PST
    Cannabis Investing News
    Cannabis Investing

    Revive Therapeutics shared positive results from their research program of cannabinoid-based therapies targeting liver diseases.

    Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) shared positive results from their research program of cannabinoid-based therapies targeting liver diseases.
    As quoted in the press release:

    “I am very pleased to have led and managed a unique drug discovery program involving phytocannabinoids, which has resulted in the discovery of novel compounds for the potential treatment of liver fibrosis and other liver disease indications that will be further explored,” said Dr. Pritesh Kumar, Scientific Advisor for the Company and Chief Executive Officer of PhytoSciences Consulting LLC. “The research that was sponsored by Revive completes a critical step in advancing novel compounds as potential therapeutics for specific liver diseases. I look forward to be the first to report these findings from the research program that I led and I am excited to contribute my expertise to further validate and potentially advance these discoveries for liver diseases.”
    “We are very pleased with the outcome of our research program for the discovery and the validation of a number of cannabinoids for the treatment of liver fibrosis,” said Craig Leon, Chief Executive of Revive. “We remain focused on building a liver disease franchise, via research and development, licensing, and strategic partnering, that will be unique to the pharmaceutical community and targeting significantly unmet medical needs in a number of liver disease indications.”

    Click here to read the full press release.

    Source: www.marketwired.com

    RVV:CC
    cannabis investingrevive therapeuticsscientific advisor
    The Conversation (0)

    Go Deeper

    AI Powered
    A colorful brain illustrating brain on pyschedelics.

    Psychedelics Stocks to Watch

    Beyond Medical Marijuana: Investment Opportunities in Cannabis-Based Biotechs

    Beyond Medical Marijuana: Investment Opportunities in Cannabis-Based Biotechs

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    extractX

    Adastra Holdings

    XTRX:CNX

    AgriFORCE Growing Systems

    AGRI

    4Front Ventures

    FFNT:CNX
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×